Oxford University and AstraZeneca vaccine results include hidden benefits

While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly lower than the results of competitors, the new vaccine bears other advantages. Phase III interim analysis of data from the Oxford University and AstraZeneca vaccine candidate AZD1222 trial has revealed that the vaccine has an efficacy of 70.4% in an average of two separate dosing regimens. The efficacy data spans 23,000 participants and 131 accrued COVID-19 cases from the UK and Brazil. The dosing regimen offering the highest efficacy of 90% involves the administration of a half dose followed a...